
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Aethlon Medical Inc (AEMD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AEMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -79.8% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.11M USD | Price to earnings Ratio - | 1Y Target Price 3.85 |
Price to earnings Ratio - | 1Y Target Price 3.85 | ||
Volume (30-day avg) 2062782 | Beta 1.75 | 52 Weeks Range 0.24 - 1.85 | Updated Date 02/9/2025 |
52 Weeks Range 0.24 - 1.85 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.79 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-12 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.46% | Return on Equity (TTM) -105.38% |
Valuation
Trailing PE - | Forward PE 0.21 | Enterprise Value 4052052 | Price to Sales(TTM) 2.37 |
Enterprise Value 4052052 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 13962000 | Shares Floating 13837396 |
Shares Outstanding 13962000 | Shares Floating 13837396 | ||
Percent Insiders 0.54 | Percent Institutions 3.09 |
AI Summary
Aethlon Medical Inc.: Comprehensive Overview
Company Profile:
History and Background:
Aethlon Medical Inc. (NASDAQ: AEMD) is a clinical-stage biopharmaceutical company focused on developing preventive and therapeutic products to address infectious diseases and life-threatening conditions. Founded in 1998, the company has headquarters in San Diego, California. Aethlon's research and development efforts have historically concentrated on utilizing therapeutic plasma exchange (TPE) technology and developing multimeric fusion proteins for various applications.
Core Business Areas:
- Preventing and treating infectious diseases: Aethlon's lead product candidate, Hemopurifier®, is a therapeutic plasma exchange (TPE) device intended to remove pathogens and inflammatory mediators from the bloodstream of patients with severe infections, sepsis, and other critical illnesses.
- Developing multimeric fusion proteins: These proteins are designed to bind to and neutralize specific viruses or toxins, offering potential treatments for diseases like Ebola virus disease, Lassa fever, and Dengue fever.
Leadership and Corporate Structure:
- President & CEO: Peter Licari, Ph.D.
- Chief Financial Officer: Thomas F. Graney IV
- Chief Medical Officer: Dr. Christopher D. Klugman
- Board of Directors: Comprises individuals with diverse expertise in pharmaceuticals, biotechnology, business, and law.
Top Products and Market Share:
Hemopurifier®:
- Description: A medical device utilizing TPE technology to remove pathogens and inflammatory mediators from the bloodstream.
- Market Share: Hemopurifier® is not yet commercially available and is currently undergoing clinical trials. Therefore, it has no current market share.
- Performance and Reception: Data from ongoing clinical trials suggest potential benefits in treating severe infections and sepsis. However, further data is needed to confirm efficacy and safety before market launch.
Comparison with Competitors:
- Hemopurifier®'s competitors in the TPE market include:
- Therakos's THERAKOS CELLUTION System
- Fresenius's MultiFlow System
- Hemopurifier® offers potential advantages:
- Smaller and more portable design
- Faster processing times
- Lower operating costs
Total Addressable Market:
- The global market for therapeutic plasma exchange (TPE) devices is estimated to be worth around USD 1.5 billion in 2023, with projections of reaching over USD 2.3 billion by 2028.
- The global market for treatments of severe infections and sepsis is estimated to be worth approximately USD 15 billion in 2023, with projections of exceeding USD 25 billion by 2028.
Financial Performance:
- Revenue: Aethlon Medical Inc. currently generates minimal revenue as it focuses on research and development.
- Net Income: The company has historically reported net losses due to ongoing R&D investments.
- Profit Margins: Profit margins are currently negative as the company is not yet profitable.
- Earnings per Share (EPS): Negative due to net losses.
- Year-over-Year Performance: Revenue and net income have remained relatively flat in recent years.
- Cash Flow and Balance Sheet: Aethlon relies on funding through equity offerings and debt financing.
Dividends and Shareholder Returns:
- Dividend History: Aethlon Medical Inc. does not currently pay dividends.
- Shareholder Returns: Shareholder returns have been negative in recent years due to the company's development stage and lack of profitability.
Growth Trajectory:
- Historical Growth: Revenue and earnings have not shown significant growth in recent years.
- Future Growth Projections: Growth will depend on successful completion of clinical trials for Hemopurifier® and potential commercialization of the device.
- Product Launches and Growth Initiatives: Continued development of Hemopurifier® and other product candidates, exploring partnerships for commercialization, and seeking additional funding for ongoing operations are key strategies for future growth.
Market Dynamics:
- Industry Trends: The global therapeutic plasma exchange market is experiencing steady growth driven by increasing prevalence of chronic diseases and rising demand for minimally invasive treatment options.
- Demand-Supply Dynamics: The demand for TPE devices is expected to continue increasing, while the supply of these devices might face some challenges due to regulatory requirements and manufacturing complexities.
- Technological Advancements: Advancements in TPE technology, such as automated systems and miniaturization of devices, are expected to drive market growth.
- Aethlon's Positioning: Aethlon is positioned in a growing market with a potentially disruptive technology; however, competition and regulatory hurdles remain challenges.
Competitors:
- Main Competitors:
- Therakos (NASDAQ: THER)
- Fresenius Medical Care (NYSE: FME)
- Baxter International Inc. (NYSE: BAX)
- Market Share Comparison:
- Therakos holds the largest market share in the TPE device market.
- Fresenius and Baxter also hold significant market shares.
- Aethlon currently holds no market share as its product is not yet commercially available.
- Competitive Advantages:
- Hemopurifier®'s potential advantages include portability, speed, and lower cost.
- Competitive Disadvantages:
- Lack of commercial experience and market presence compared to established competitors.
Potential Challenges and Opportunities:
Challenges:
- Completion of clinical trials and regulatory approval for Hemopurifier®: Demonstrating safety and efficacy is crucial for market entry.
- Competition in the TPE market: Established players with larger market shares pose challenges.
- Securing funding for ongoing operations and future expansion: Aethlon may require additional capital to achieve its goals.
Opportunities:
- Commercialization of Hemopurifier®: Potential for significant revenue generation and market penetration.
- Expanding product portfolio: Developing additional treatments for infectious diseases and other therapeutic areas.
- Strategic partnerships: Collaborations with established companies could accelerate product development and market access.
Recent Acquisitions:
Aethlon Medical Inc. has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on the available information, Aethlon Medical Inc. receives an AI-based fundamental rating of 5 out of 10. This rating reflects the company's early-stage development, potential market opportunity, and competitive landscape. The rating considers various factors, including financial health, market position, and future prospects, but remains cautious due to the high-risk nature of its development stage.
Sources and Disclaimers:
Sources:
- Aethlon Medical Inc. website
- Securities and Exchange Commission (SEC) filings
- Market research reports
Disclaimer:
This overview is for informational purposes only and should not be considered investment advice. Investing in early-stage companies like Aethlon Medical Inc. involves significant risk, and potential investors should carefully consider all aspects of the company before making any investment decisions.
About Aethlon Medical Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2001-01-02 | CEO, CFO, Secretary & Director Mr. James B. Frakes M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 14 | Website https://www.aethlonmedical.com |
Full time employees 14 | Website https://www.aethlonmedical.com |
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.